News for Pharmadrug Inc. (PHRX.CN)

PharmaDrug's Sairiyo Therapeutics Announces Successful Completion of Stability Study of PD-001 (Patented Reformulated Cepharanthine) to Support Use in Phase 1 Study for Viral Infectious Diseases

PharmaDrug's Sairiyo Therapuetics Provides Strategic Plans to Advance PD-001 (Patented Reformulated Cepharanthine) for Viral Infectious Diseases

TORONTO, Aug. 21, 2024 (GLOBE NEWSWIRE) — PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company,…

PharmaDrug's Sairiyo Therapeutics Submits Clinical Trial Application for Phase 1 Study of Patented Reformulated Cepharanthine

PharmaDrug Inc. , a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances, natural medicines, and previously approved drugs, is pleased...

TORONTO, Feb. 21, 2024 (GLOBE NEWSWIRE) — PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical…

PharmaDrug Inc. , is pleased to announce the closing of its previously announced non-brokered private placement raising total gross proceeds of $326,000 .Pursuant to the Offering the Company issued...

Pharmadrug Inc. announced that it has appointed Kyle Appleby as its Chief Financial Officer in place of the company's former Chief Financial Officer, Keith Li. Kyle Appleby is an experienced public...

PharmaDrug Inc. , announced today that it will be proceeding with the consolidation of its common shares on the basis of seven pre consolidated Common Shares into one post consolidated Common...

PharmaDrug Inc. , announced today that, further to its press release dated September 6, 2023, Mr. Daniel Cohen will not be standing for re-election as a director of the Company at the upcoming...

Effective immediately, the following companies are suspended pursuant to CSE Policy 3. The suspensions are considered Regulatory Halts as defined in National Instrument 23-101 Trading Rules. ... | May 8, 2023

A glance at some of the day's highlights from the Proactive Investors US and Canada newswires